Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
28 Cards in this Set
- Front
- Back
|
307. 2 Proton Pump Inhibitors?
|
a. Omeprazole
b. Lansoprazole |
|
|
308. MOA of Proton Pump inhibitors?
|
a. Irreversibly inhibit H+/K+-ATPase in stomach parietal cells.
|
|
|
309. Clinical use of Proton Pump inhibitors?
|
a. Peptic ulcer, gastritis, esophageal reflux, ZES.
|
|
|
310. Clinical use of Bismuth, sucralfate?
|
a. ↑ Ulcer healing.
b. Traveler’s diarrhea. |
|
|
311. MOA of Bismuth, Sucralfate?
|
a. Bind to ulcer base, providing physical protection, and allow HCO3 secretion to re-establish pH gradient in the mucous layer.
|
|
|
312. Triple therapy of H. Pylori ulcers?
|
1. Metronidazole
2. Amoxacillin (or Tetracycline) 3. Bismuth. b. Can also use PPI |
|
|
313. Misoprostol MOA?
|
a. A PGE1 analogue.
b. ↑ Production and secretion of gastric mucous barrier. c. ↓ Acid production. |
|
|
314. Clinical use of Misoprostol?
|
a. Prevention of NSAID-induced peptic ulcers.
b. Maintenance of a patent PDA. c. To induce labour |
|
|
315. Toxicity of Misoprostol?
|
a. Diarrhoea.
b. Contraindicated in women of childbearing potential (abortifacient). |
|
|
316. 2 Muscarinic antagonists for Peptic ulcers?
|
a. Pirenzepine, propantheline.
b. Rarely used |
|
|
317. Moa of muscarinic antagonists in gut?
|
a. Block M1 receptors on ECL cells (↓ histamine secretion) and M3 receptors on parietal cells (↓ H+ secretion).
|
|
|
318. Toxicity of muscarinic antagonists?
|
a. Tachycardia
b. Dry mouth c. Difficulty focusing eyes. |
|
|
319. Octreotide MOA and use?
|
a. Somatostatin analogue.
b. Used for: 1. Acute variceal bleeds 2. Acromegaly 3. VIPoma 4. Carcinoid tumours. |
|
|
320. Toxicity of Octreotide?
|
a. Nausea
b. Cramps c. Steatorrhea. |
|
|
321. SE of Aluminum hydroxide antacid?
|
a. Constipation and hypophosphatemia
b. Proximal muscle weakness c. Osteodystrophy d. Seizures e. “AluMINIMUM amount of feces”. |
|
|
322. SE of magnesium hydroxide antacid?
|
a. Diarrhea
b. Hyporeflexia c. Hypotension d. Cardiac arrest |
|
|
323. SE of Calcium carbonate antacid?
|
a. Hypercalcemia
b. Rebound acid ↑. c. Can chelate and ↓ effectiveness of other drugs (e.g. tetracycline). |
|
|
324. Infliximab MOA and use?
|
a. A monoclonal antibody to TNF (Proinflammatory cytokine)
b. Used for Crohn’s disease, RA. |
|
|
325. AE of Infliximab?
|
a. Respiratory infection (including reactivation of latent TB)
b. Fever c. Hypotension. |
|
|
326. MOA of sulfasalazine?
|
a. A combination of sulfapyridine (antibacterial) and 5-aminosalicylic acid (anti-inflammatory).
b. Activated by colonic bacteria. |
|
|
327. Clinical use of sulfasalazine?
|
a. UC, Crohn’s.
|
|
|
328. AE of sulfasalazine?
|
a. Malaise, nausea, sulfonamide toxicity, reversible oligospermia.
|
|
|
329. MOA of Ondansetron and indication?
|
a. 5-HT3 antagonist.
b. Powerful central-acting antiemetic. c. Controls vomiting postoperatively and in pts undergoing cancer chemo. |
|
|
330. Toxicity of Ondansetron?
|
a. HA, constipation.
|
|
|
331. MOA of Metoclopramide?
|
a. D2 receptor antagonist.
b. ↑ resting tone, contractility, LES tone, motility. c. Does not influence colon transport time. |
|
|
332. Clinical use of Metoclopramide?
|
a. Diabetic and post-surgery gastroparesis.
|
|
|
333. Toxicity of metoclopramide?
|
a. ↑ Parkinsonian effects.
b. Restlessness, drowsiness, fatigue, depression, nausea, diarrhea. c. Drug interaction w/digoxin and diabetic agents. d. Contraindicated in pts w/small bowel obstruction. |
|
|
334. Donzo
|
334. Donzo
|
